Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nafamostat
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Talphera Enrolls First Patient in Trial for Nafamostat in Extracorporeal Circuit
Details : Talphera's lead product candidate, Niyad is a lyophilized formulation of nafamostat mesylate and is currently being studied under an IDE as an anticoagulant for the extracorporeal circuit.
Product Name : Niyad
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 19, 2024
Lead Product(s) : Nafamostat
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : XOMA
Deal Size : $8.0 million
Deal Type : Acquisition
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
Details : XOMA acquired an economic interest in DSUVIA® (sufentanil sublingual tablet), an opioid agonist, indicated for use in adults, for the management of acute pain, from Talphera.
Product Name : Dsuvia
Product Type : Controlled Substance
Upfront Cash : Undisclosed
January 18, 2024
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : XOMA
Deal Size : $8.0 million
Deal Type : Acquisition